Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: Week-192 overall and subgroup analyses from STARTMRK

Edwin Dejesus, Jürgen Rockstroh, Jeffrey Lennox, Michael Saag, Adriano Lazzarin, Jing Zhao, Hong Wan, Anthony Rodgers, Monica Walker, Michael Miller, Mark Dinubile, Bach Yen Nguyen, Hedy Teppler, Randi Leavitt, Peter Sklar

Research output: Contribution to journalArticle

Abstract

We compared 4 years of antiretroviral therapy with tenofovir/emtricitabine and either raltegravir or efavirenz from the ongoing STARTMRK study of treatment-naïve HIV-infected patients. Through 192 weeks, raltegravir produced durable and consistent viral suppression and immune restoration compared with efavirenz irrespective of baseline demographic and prognostic factors, including in patients with high viral loads.

Original languageEnglish
Pages (from-to)228-232
Number of pages5
JournalHIV Clinical Trials
Volume13
Issue number4
DOIs
Publication statusPublished - Jan 1 2012

    Fingerprint

Keywords

  • efavirenz
  • raltegravir
  • STARTMRK
  • subgroups

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Dejesus, E., Rockstroh, J., Lennox, J., Saag, M., Lazzarin, A., Zhao, J., Wan, H., Rodgers, A., Walker, M., Miller, M., Dinubile, M., Nguyen, B. Y., Teppler, H., Leavitt, R., & Sklar, P. (2012). Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: Week-192 overall and subgroup analyses from STARTMRK. HIV Clinical Trials, 13(4), 228-232. https://doi.org/10.1310/hct1304-228